pramiracetam

{{short description|Chemical compound}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 477172019

| IUPAC_name = N-[2-(Diisopropylamino)ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide

| image = Pramiracetam.svg

| image_class = skin-invert-image

| width = 150px

| image2 = Pramiracetam3d.png

| image_class2 = bg-transparent

| tradename = Pramistar

| Drugs.com = {{drugs.com|international|pramistar}}

| pregnancy_category =

| legal_AU = S4

| legal_US = Not FDA approved

| routes_of_administration = Oral

| bioavailability =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 68497-62-1

| ATC_prefix = N06

| ATC_suffix = BX16

| PubChem = 51712

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = 46801

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 4449F8I3LE

| ChEMBL_Ref = {{ebicite|correct|EBI}}

| ChEMBL = 159776

| C=14 | H=27 | N=3 | O=2

| smiles = O=C1N(CC(=O)NCCN(C(C)C)C(C)C)CCC1

| StdInChI_Ref = {{stdinchicite|correct|chemspider}}

| StdInChI = 1S/C14H27N3O2/c1-11(2)17(12(3)4)9-7-15-13(18)10-16-8-5-6-14(16)19/h11-12H,5-10H2,1-4H3,(H,15,18)

| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}

| StdInChIKey = ZULJGOSFKWFVRX-UHFFFAOYSA-N

}}

Pramiracetam is a nootropic agent belonging to the racetam family of drugs. It is marketed by Menarini under the brand name Pramistar as a treatment for memory and attention deficits in aging people with neurodegenerative and vascular dementias in Italy and some Eastern European countries.AIFA [https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/farmaco?farmaco=028021 Pramistar authorizations in the Agenzia Italiana del Farmaco Database] Page accessed August 2, 2015. [https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000211_028021_FI.pdf&retry=0&sys=m0b1l3 Italian Label], linked from that site]Drugs.com [https://www.drugs.com/international/pramiracetam.html Drugs.com International listings for pramiracetam] Page accessed August 2, 2015Italian marketing authorization for the brand name Remen has been revoked per the [https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/farmaco?farmaco=027908 AIFA database], as has the marketing authorization for the brand name Neupramir, per the [https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/farmaco?farmaco=028029 AIFA database], each checked on August 2, 2015. Main page at AIFA for pramiracetam is [https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/cerca-per-principio-attivo?princ_att=Pramiracetam here]

Pramiracetam was discovered by scientists at Parke-Davis, at that time a division of Warner-Lambert, in the late 1970s; patents expired in 1996. Warner-Lambert conducted clinical trials in Alzheimer's Disease and abandoned that indication after Phase II trials showed mixed results; it then began to develop it as an orphan drug as an adjunct to electroconvulsive therapy for major depressive disorder, in part to take advantage of the administrative exclusivity provided by the orphan status. It licensed European rights to Menarini which continued developing it for dementias, and in 1991 it licensed US and other non-European rights to Cambridge Neuroscience, Inc, (CNI) which pursued the ECT indication, as well as a use in restoring cognitive function after stroke or traumatic brain injury.Staff, The Pink Sheet. May 27, 1991 [https://www.pharmamedtechbi.com/publications/the-pink-sheet/53/021/cambridge-neuroscience-developing-warnerlamberts-pramiracetam Cambridge Neuroscience Developing Warner-Lambert's Pramiracetam] CNI obtained the orphan designation for the ECT use from the FDA in 1991, which was later withdrawn when CNI abandoned the drug.FDA [http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=061691 Orphan Drug Designations and Approvals Database]{{dead link|date=May 2025|bot=medic}}{{cbignore|bot=medic}} Page accessed August 2, 2015

CNI conducted a clinical trial in four people who had cognitive problems following a head injury. Trials conducted by or on behalf of Menarini and Warner-Lambert included two small trials conducted in Ukraine, one in people with cerebrovascular disease and another in people with concussion. Another small trial was performed in Italy, on healthy people in whom amnesia was induced with scopolamine.{{cite journal | vauthors = Malykh AG, Sadaie MR | title = Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders | journal = Drugs | volume = 70 | issue = 3 | pages = 287–312 | date = February 2010 | pmid = 20166767 | doi = 10.2165/11319230-000000000-00000 }}